Source-grounded facts extracted from Immuneering Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Mallory Morales changed role as Senior Vice President Finance, Chief Accounting Officer at Immuneering Corp.
“The Board also designated Mr. Gengos as the Company’s principal financial officer as of the Effective Date, succeeding Mallory Morales in such role. In her ongoing role as Senior Vice President Finance, Chief Accounting Officer, Ms. Morales will continue to serve as the Company’s principal accounting officer.”
Andrew Gengos was appointed as Chief Financial Officer and Treasurer at Immuneering Corp.
“On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually commences employment with the Company, the “Effective Date”).”
Immuneering Corp shareholders approved Ratification of the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-11 meeting.
“Item 2 — Ratification of the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 42,142,848 1,920,218 431,993 0”
Immuneering Corp shareholders approved Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders at the 2026-06-11 meeting.
“Item 1 — Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes AGAINST Votes WITHHELD Broker Non-Votes Peter Feinberg 26,420,287 0 2,008,073 16,066,699 Laurie B. Keating 27,121,501 0 1,306,859 16,066,699”
Immuneering Corp reported the first quarter ended March 31, 2026 results: net income $13.5 million, or $0.21 per share, EPS $0.21 per share.
“Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.”
Immuneering Corp issued $25.0 million of shares of the Company's Class A common stock or, in certain circumstances, shares of the Company's non-voting Class B common stock of common stock to Aventis Inc. for The price per Share will be the price per share of Class A Common Stock to the public in the Public Offering as set forth on the cover of the definitive prospec.
“On September 24, 2025, Immuneering Corporation (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with Aventis Inc. (the "Investor"), a wholly owned subsidiary of Sanofi, a French société anonyme, pursuant to which the Company, in a private placement transaction (the "Private Placement"), agreed to issue and sell to the Investor $25.0 million of shares (the "Class A Shares") of the Company's Class A common stock, par value $0.001 per share ("Class A Common Stock"), or in certain circumstances in lieu of Class A Shares, shares (the "Class B Shares" and, together with the Class A Shares, collectively, the "Shares") of the Company's non-voting Class B common stock, par value $0.001 per share ("Class B Common Stock"), subject to and contingent upon the closing of a firm commitment underwritten public offering of Class A Common Stock by the Company that results in gross proceeds to the Company of at least $75.0 million and the pricing of which is publicl”
Immuneering Corp reported the first quarter ended March 31, 2024 results: net income Net loss attributable to common stockholders was $14.3 million, or $0.49 per share, EPS $0.49 per share.
“Immuneering Corporation (the “Company”) announced its financial results for the quarter ended March 31, 2024”
Thomas J. Schall, Ph.D. was appointed as Director at Immuneering Corp.
“On March 11, 2024, the Board of Directors of Immuneering Corporation (“we,” “our” and “us”) appointed Thomas J. Schall, Ph.D. to serve as a member of our Board of Directors as a Class I Director.”
Immuneering Corp reported financial results for the fourth quarter and full year ended December 31, 2023.
“today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business updates.”
Immuneering Corp: Amended and restated bylaws to address universal proxy rules, enhance stockholder nomination and proposal procedures, and require white proxy card for stockholder solicitations (effective 2024-02-01).
“On February 1, 2024, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) adopted amendments to the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.”
Immuneering Corp reported for the quarter ended September 30, 2023 results: net income $12.6 million, EPS $0.43 per share.
“Net loss attributable to common stockholders was $12.6 million, or $0.43 per share, for the quarter ended September 30, 2023”
Immuneering Corp reported the second quarter ended June 30, 2023 results: net income $12.2 million, or $0.43 per share, EPS $0.43 per share.
“Net loss attributable to common stockholders was $12.2 million, or $0.43 per share, for the quarter ended June 30, 2023, compared to $11.5 million, or $0.44 per share, for the quarter ended June 30, 2022.”
Immuneering Corp shareholders approved Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. at the 2023-06-14 meeting.
“Votes Votes FOR Votes AGAINST ABSTAINED Broker Non-Votes 22,595,867 14,843 100 0 Based on the foregoing votes, Peter Feinberg and Laurie B.”
Immuneering Corp shareholders approved Election of two Class II directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. at the 2023-06-14 meeting.
“Peter Feinberg 18,604,285 0 659,292 3,347,233 Laurie B. Keating 18,640,672 0 622,905 3,347,233”
Mallory Morales was appointed as Chief Accounting Officer and Treasurer at Immuneering Corp.
“On June 13, 2023, the Board of Directors (the "Board") of Immuneering Corporation (the “Company”) appointed Mallory Morales as the Company's Chief Accounting Officer and Treasurer, effective July 1, 2023 (the "Promotion Effective Date").”
Immuneering Corp reported the first quarter ended March 31, 2023 results: net income $13.6 million, EPS $0.51 per share.
“Net loss attributable to common stockholders was $13.6 million, or $0.51 per share, for the first quarter ended March 31, 2023, compared to $12.9 million, or $0.49 per share, for the first quarter ended March 31, 2022.”
Immuneering Corp entered into Underwriting Agreement with Jefferies LLC, Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of the several underwriters valued at approximately $27.8 million (effective 2023-04-18).
“On April 18, 2023, Immuneering Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of the several underwriters listed on Schedule I attached thereto (the “Underwriters”), in connection with the public offering, issuance and sale by the Company of 2,727,273 shares of the Company’s Class A common stock, $0.001 par value per share (the “Common Stock”), at a public offering price of $11.00 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-266738) and a related prospectus supplement filed with the Securities and Exchange Commission (the “Offering”).”
Immuneering Corp reported financial results for the quarter and full-year ended December 31, 2022.
“On March 6, 2023, Immuneering Corporation (the “Company”) announced its financial results for the quarter and full-year ended December 31, 2022 and provided business updates.”
Immuneering Corp reported the third quarter ended September 30, 2022 results: net income $12.8 million, or $0.49 per share, EPS $0.49 per share. Guidance reaffirmed.
“Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today reported financial results for the third quarter ended September 30, 2022, and provided recent business highlights.”
Mallory Morales was appointed as principal financial officer, principal accounting officer and Treasurer at Immuneering Corp.
“On July 24, 2022, the Board of Directors of the Company appointed Mallory Morales, the Company’s Vice President, Finance, as principal financial officer, principal accounting officer and Treasurer of the Company, contingent and effective upon Mr. Amin ceasing to serve as the Company’s Chief Financial Officer, principal financial officer, principal accounting officer and Treasurer (the “Effective Date”).”
Biren Amin departed as Chief Financial Officer at Immuneering Corp.
“On July 20, 2022, Biren Amin notified Immuneering Corporation (the “Company”) that he plans to step down as Chief Financial Officer, principal financial officer, principal accounting officer and Treasurer of the Company to pursue another professional opportunity.”
Diana F. Hausman, MD was appointed as Class I Director at Immuneering Corp.
“On January 14, 2022, the Board of Directors of Immuneering Corporation (the “Company”) appointed Diana F. Hausman, MD to serve as a member of the Board of Directors as a Class I Director.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.